Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ALDXNASDAQ:EPRXNASDAQ:GLSINASDAQ:PRAN On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeALDXAldeyra Therapeutics$2.35+10.8%$2.51$1.14▼$7.20$140.76M0.92797,866 shs914,542 shsEPRXEupraxia Pharmaceuticals$4.07+3.2%$3.62$2.20▼$4.48$145.73M0.6613,193 shs11,276 shsGLSIGreenwich LifeSciences$9.55-0.9%$9.62$8.06▼$18.75$127.66M1.7446,311 shs33,057 shsPRANAlterity Therapeutics$4.58-0.4%$1.41$1.09▼$2.91$40.77M1.05130,956 shs5,188 shs12 Stocks Corporate Insiders are AbandoningIf a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know? MarketBeat just compiled its list of the twelve stocks that corporate insiders are abandoning. Complete the form below to see which companies made the list.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceALDXAldeyra Therapeutics+10.85%+6.82%-16.37%-61.79%-38.80%EPRXEupraxia Pharmaceuticals+3.17%+5.31%+1.50%+6.14%+50.56%GLSIGreenwich LifeSciences-0.93%-4.31%-4.40%-20.08%-31.74%PRANAlterity Therapeutics+2.21%+8.22%+33.70%+29.20%+135.87%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationALDXAldeyra Therapeutics2.5465 of 5 stars3.53.00.00.02.21.70.6EPRXEupraxia Pharmaceuticals1.9934 of 5 stars3.71.00.00.01.80.00.6GLSIGreenwich LifeSciences2.0993 of 5 stars3.50.00.00.03.33.30.0PRANAlterity TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceALDXAldeyra Therapeutics 3.00Buy$9.50304.26% UpsideEPRXEupraxia Pharmaceuticals 3.33Buy$10.50158.30% UpsideGLSIGreenwich LifeSciences 3.00Buy$39.00308.38% UpsidePRANAlterity Therapeutics 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest PRAN, ALDX, GLSI, and EPRX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/19/2025ALDXAldeyra TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$10.00 ➝ $10.004/21/2025GLSIGreenwich LifeSciencesHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$38.00 ➝ $39.004/7/2025ALDXAldeyra TherapeuticsBTIG ResearchSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$11.00 ➝ $9.004/4/2025ALDXAldeyra TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$10.00 ➝ $10.00(Data available from 6/4/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookALDXAldeyra TherapeuticsN/AN/AN/AN/A$2.04 per shareN/AEPRXEupraxia PharmaceuticalsN/AN/AN/AN/A$0.03 per shareN/AGLSIGreenwich LifeSciencesN/AN/AN/AN/A$0.52 per shareN/APRANAlterity Therapeutics$150K271.79N/AN/A$1.40 per share3.27Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateALDXAldeyra Therapeutics-$37.54M-$0.97N/AN/AN/AN/A-43.01%-33.62%7/30/2025 (Estimated)EPRXEupraxia Pharmaceuticals-$28.22M-$0.76N/AN/AN/AN/A-219.64%-96.00%8/6/2025 (Estimated)GLSIGreenwich LifeSciences-$8.89M-$1.26N/AN/AN/AN/A-185.12%-164.27%8/12/2025 (Estimated)PRANAlterity Therapeutics-$6.40M-$0.70N/A∞N/AN/AN/AN/AN/ALatest PRAN, ALDX, GLSI, and EPRX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/20/2025Q1 2025GLSIGreenwich LifeSciences-$0.24-$0.25-$0.01-$0.25N/AN/A5/14/2025Q1 2025ALDXAldeyra Therapeutics-$0.25-$0.17+$0.08-$0.17($0.80) millionN/A5/6/2025Q1 2025EPRXEupraxia Pharmaceuticals-$0.19-$0.21-$0.02-$0.21N/AN/A4/15/2025Q4 2024GLSIGreenwich LifeSciences-$0.21-$0.61-$0.40-$0.61N/AN/A3/20/2025Q4 2024EPRXEupraxia Pharmaceuticals-$0.20-$0.21-$0.01-$0.21N/AN/A3/6/2025Q4 2024ALDXAldeyra Therapeutics$0.03-$0.27-$0.30-$0.27N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthALDXAldeyra TherapeuticsN/AN/AN/AN/AN/AEPRXEupraxia PharmaceuticalsN/AN/AN/AN/AN/AGLSIGreenwich LifeSciencesN/AN/AN/AN/AN/APRANAlterity TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioALDXAldeyra Therapeutics0.186.806.80EPRXEupraxia PharmaceuticalsN/A4.174.17GLSIGreenwich LifeSciencesN/A6.916.91PRANAlterity TherapeuticsN/A4.37N/ACompare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipALDXAldeyra Therapeutics59.71%EPRXEupraxia PharmaceuticalsN/AGLSIGreenwich LifeSciences4.16%PRANAlterity Therapeutics3.63%Insider OwnershipCompanyInsider OwnershipALDXAldeyra Therapeutics9.60%EPRXEupraxia PharmaceuticalsN/AGLSIGreenwich LifeSciences51.67%PRANAlterity Therapeutics38.80%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableALDXAldeyra Therapeutics1559.90 million54.49 millionOptionableEPRXEupraxia Pharmaceuticals2935.85 millionN/AN/AGLSIGreenwich LifeSciences313.37 million6.35 millionNot OptionablePRANAlterity Therapeutics148.90 millionN/ANot OptionablePRAN, ALDX, GLSI, and EPRX HeadlinesRecent News About These CompaniesIs Alterity Therapeutics Limited (ATHE) the Best Australian Stock to Buy According to Analysts?May 15, 2025 | msn.comAlterity wins FDA fast-track for ATH434 – but with 9B shares on issue, impact dilutedMay 6, 2025 | msn.comAlterity Therapeutics Reveals Top Option HoldersApril 21, 2025 | tipranks.comAlterity Therapeutics completes placementApril 9, 2025 | uk.investing.comAlterity Therapeutics announces regulatory noticeApril 9, 2025 | uk.investing.comAlterity Therapeutics to Deliver an Oral Presentation of the Positive ATH434 Phase 2 Trial Results at the American Academy of Neurology Annual MeetingApril 3, 2025 | markets.businessinsider.comAlterity Therapeutics completes last patient visit in ATH434-202 Phase 2 trialMarch 28, 2025 | markets.businessinsider.comAlterity Therapeutics (ATHE): Among the Best Australian Stocks to Buy According to BillionairesMarch 10, 2025 | msn.comAlterity Therapeutics Ltd PBNMarch 1, 2025 | morningstar.comAlterity Therapeutics Expands Capital with New Securities QuotationFebruary 18, 2025 | tipranks.comAlterity Therapeutics to List New Securities on ASXFebruary 16, 2025 | tipranks.comAlterity secures funding to advance MSA drug developmentFebruary 10, 2025 | msn.comAlterity Therapeutics raises A$40M in placementFebruary 10, 2025 | markets.businessinsider.comAlterity Therapeutics (ASX:ATH) shareholder returns have been stellar, earning 260% in 1 yearFebruary 8, 2025 | finance.yahoo.comAlterity Therapeutics reports compliance with Takeovers PanelFebruary 5, 2025 | msn.comAlterity Therapeutics announces securities noticeFebruary 4, 2025 | msn.comAlterity Therapeutics Completes Significant Share IssuanceFebruary 3, 2025 | tipranks.comAlterity Therapeutics announces ATH434 Phase 2 trial resultsJanuary 30, 2025 | msn.comAlterity Therapeutics Stock Doubles Premarket On Positive MSA Trial Results: Retail Excitement SoarsJanuary 30, 2025 | msn.comAlterity Therapeutics price target raised to $12 from $8 at MaximJanuary 30, 2025 | markets.businessinsider.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimePRAN, ALDX, GLSI, and EPRX Company DescriptionsAldeyra Therapeutics NASDAQ:ALDX$2.35 +0.23 (+10.85%) Closing price 06/3/2025 04:00 PM EasternExtended Trading$2.33 -0.02 (-1.06%) As of 04:02 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Aldeyra Therapeutics is a clinical-stage biotechnology company focused on the development of novel therapies with the potential to improve the lives of patients with immune-mediated diseases. Two of the company's lead compounds, reproxalap and ADX-629, target reactive aldehyde species (RASP), which are elevated in ocular and systemic inflammatory disease, leading to elevated levels of cytokine release via activation of a broad array of inflammatory factors, including NF-κB, inflammasomes, and Scavenger Receptor A. Reproxalap is being evaluated in Phase 3 clinical trials in patients with dry eye disease and allergic conjunctivitis. The company's clinical pipeline also includes ADX-2191, a dihydrofolate reductase inhibitor in Phase 3 testing for proliferative vitreoretinopathy, and ADX-1612, a chaperome inhibitor in Phase 2 testing for COVID-19 and ovarian cancer.Eupraxia Pharmaceuticals NASDAQ:EPRX$4.07 +0.13 (+3.17%) Closing price 06/3/2025 03:59 PM EasternExtended Trading$4.03 -0.04 (-0.86%) As of 06/3/2025 04:17 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Eupraxia Pharmaceuticals Inc. is a clinical-stage biotechnology company. It focused on the development of locally delivered, extended-release products that have the potential to address therapeutic areas with high unmet medical need. Th company's lead product candidate includes EP-104IAR, for the treatment of pain due to osteoarthritis of the knee. Eupraxia Pharmaceuticals Inc. is based in VICTORIA, BC.Greenwich LifeSciences NASDAQ:GLSI$9.55 -0.09 (-0.93%) Closing price 06/3/2025 04:00 PM EasternExtended Trading$9.56 +0.01 (+0.10%) As of 06/3/2025 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Greenwich LifeSciences, Inc., a clinical-stage biopharmaceutical company, develops novel cancer immunotherapies for breast cancer and other HER2/neu-expressing cancers. Its lead product candidate is GP2, an immunotherapy, which is in Phase III clinical trial to prevent breast cancer recurrences in patients who have previously undergone surgery. The company was formerly known as Norwell, Inc. and changed its name to Greenwich LifeSciences, Inc. in March 2018. Greenwich LifeSciences, Inc. was incorporated in 2006 and is headquartered in Stafford, Texas.Alterity Therapeutics NASDAQ:PRANAlterity Therapeutics Ltd. engages in the development of therapeutic drugs designed to treat the underlying causes of degeneration of the brain as the aging process progresses. It focuses on Parkinson's movement disorders, Alzheimer's disease, Huntington disease, and other neurodegenerative disorders. The company was founded by Geoffrey Paul Kempler on November 11, 1997 and is headquartered in Melbourne, Australia. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas 3 Reasons Amazon Could Be the Best Tech Performer in June Ollie’s Q1 Earnings: The Good, the Bad, and What’s Next Applied Digital: CoreWeave’s AI Deal Lights a $7 Billion Fuse Qualcomm: A Technical Deep-Dive Confirms the Worst Rocket Lab Expands Into Payloads: Should You Be Paying Attention? Steel Dynamics Shares Climb After Tariff Announcement Palantir Soars on Government Deals as Valuation Debate Lingers Broadcom Earnings Preview: AVGO Stock Near Record Highs Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
